Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.
Devillier R, Mansat-De Mas V, Gelsi-Boyer V, Demur C, Murati A, Corre J, Prebet T, Bertoli S, Brecqueville M, Arnoulet C, Recher C, Vey N, Mozziconacci MJ, Delabesse E, Birnbaum D. Devillier R, et al. Oncotarget. 2015 Apr 10;6(10):8388-96. doi: 10.18632/oncotarget.3460. Oncotarget. 2015. PMID: 25860933 Free PMC article.
Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative study.
Prebet T, Etienne A, Devillier R, Romeo E, Charbonnier A, D'incan E, Esterni B, Arnoulet C, Blaise D, Vey N. Prebet T, et al. Among authors: devillier r. Cancer. 2011 Mar 1;117(5):974-81. doi: 10.1002/cncr.25554. Epub 2010 Oct 18. Cancer. 2011. PMID: 20957721 Free article.
The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT.
Devillier R, Crocchiolo R, Castagna L, Fürst S, El Cheikh J, Faucher C, Prebet T, Etienne A, Chabannon C, Vey N, Esterni B, Blaise D. Devillier R, et al. Bone Marrow Transplant. 2012 May;47(5):639-45. doi: 10.1038/bmt.2012.3. Epub 2012 Feb 6. Bone Marrow Transplant. 2012. PMID: 22307016
Myeloid malignancies: mutations, models and management.
Murati A, Brecqueville M, Devillier R, Mozziconacci MJ, Gelsi-Boyer V, Birnbaum D. Murati A, et al. Among authors: devillier r. BMC Cancer. 2012 Jul 23;12:304. doi: 10.1186/1471-2407-12-304. BMC Cancer. 2012. PMID: 22823977 Free PMC article. Review.
Donor CD3(+) lymphocyte infusion after reduced intensity conditioning allogeneic stem cell transplantation: single-center experience.
El-Cheikh J, Crocchiolo R, Furst S, Ladaique P, Castagna L, Faucher C, Calmels B, Oudin C, Lemarie C, Granata A, Devillier R, Vey N, Bouabdallah R, Chabannon C, Blaise D. El-Cheikh J, et al. Among authors: devillier r. Exp Hematol. 2013 Jan;41(1):17-27. doi: 10.1016/j.exphem.2012.09.008. Epub 2012 Sep 25. Exp Hematol. 2013. PMID: 23022128
Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft-versus-host disease in reduced-intensity conditioning transplantation for hematologic diseases.
Crocchiolo R, Esterni B, Castagna L, Fürst S, El-Cheikh J, Devillier R, Granata A, Oudin C, Calmels B, Chabannon C, Bouabdallah R, Vey N, Blaise D. Crocchiolo R, et al. Among authors: devillier r. Cancer. 2013 Mar 1;119(5):986-92. doi: 10.1002/cncr.27858. Epub 2012 Oct 23. Cancer. 2013. PMID: 23096591 Free article.
106 results